First line of the email MUST contain NCT # and Site #.
CONTACT
Lead
Mirati Therapeutics Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.
You may not be if
Participants not receiving clinical benefit from parent study drug as assessed by the investigator.
Clareo Health | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
